Study summary
Azetukalner reduced focal seizures in a dose-dependent way
52.8%median drop in monthly seizures with 25 mg, vs 18.2% with placebo
What was tested
XEN1101 (azetukalner) at three doses or placebo for 8 weeks in adults with focal seizures despite 1 to 3 medicines.
What they found
- Median seizure reduction was 52.8% with 25 mg vs 18.2% with placebo.
- Side effects were similar to common seizure medicines.
What it means
Led to the phase 3 X-TOLE program.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.